Experience has shown that it is advisable to stipulate more precisely the cases in which the results of toxicological and pharmacological tests or clinical trials do not have to be provided with a view to obtaining authorization for a medicinal product which is essentially similar to an authorized product, while ensuring that innovative firms are not placed at a disadvantage.
Recital 9, Directive (EU) 2001/83
Judgment of the General Court (Second Chamber) of 15 September 2015. Novartis Europharm Ltd v European Commission.Decision
Article 10(1) of Directive 2001/83 — which provides for the possibility of derogating from the requirement laid down in Article 8(3)(i) of that directive to provide the results of pharmaceutical pre-clinical tests and clinical trials for …
15 Sep 2015 · 62012TJ0472
Judgment of the General Court (Seventh Chamber, Extended Composition) of 5 May 2021. Pharmaceutical Works Polpharma S.A. v European MedicineDecision
Article 10(1) of Directive 2001/83 (see paragraph 8 above) seeks to reconcile, on the one hand, the provision of adequate protection for the research and development work undertaken by innovative pharmaceutical companies and, on the other, …
5 May 2021 · 62018TJ0611
Opinion of Advocate General Wahl delivered on 20 May 2014. Olainfarm AS v Latvijas Republikas Veselības ministrija and Zāļu valsts aģentūra.Decision
However, an important proviso applies here. Recourse to the exception concerning generics in Article 10 of Directive 2001/83 should not place manufacturers that invest in research in order to develop new medicinal products at a competitive …
20 May 2014 · 62013CC0104
Opinion of Advocate General Bobek delivered on 21 December 2016.Decision
The length of the regulatory data protection period and the possibility to resort to the abridged procedure for marketing authorisation reflects a balance that the EU legislature decided to strike between protection of innovative companies …
21 Dec 2016 · 62015CC0629
Opinion of Advocate General Medina delivered on 6 October 2022. European Commission and Others v Pharmaceutical Works Polpharma S.A.Decision
Recitals 9 and 12 of Directive 2001/83 state: Experience has shown that it is advisable to stipulate more precisely the cases in which the results of toxicological and pharmacological tests or clinical trials do not have to be provided …
6 Oct 2022 · 62021CC0438
Opinion of Mr Advocate General Mazák delivered on 26 March 2009. The Queen, on the application of Generics (UK) Ltd v Licensing Authority.Decision
Furthermore, Generics considers that the rationale for the abridged procedure is to strike a balance between two sets of competing interests, namely: (i) to facilitate the entry onto the market of generic products, by relieving generic …
26 Mar 2009 · 62007CC0527
Judgment of the Court (Fourth Chamber) of 16 March 2023. European Commission and Others v Pharmaceutical Works Polpharma S.A.Decision
Recitals 9 and 12 of Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use (OJ 2001 L 311, p. 67), as amended by Directive 2012/26/EU of the …
16 Mar 2023 · 62021CJ0438
Opinion of Advocate General Kokott delivered on 4 June 2020. H. Lundbeck A/S and Lundbeck Ltd v European Commission.Decision
That latter aspect is of particular importance in the field of medicinal products, where the promotion of research by originator undertakings must be reconciled with the public interest in the marketing of generic medicinal products, which …
4 Jun 2020 · 62016CC0591
Judgment of the Court (Second Chamber) of 23 April 2026. EG Labo Laboratoires Eurogenerics SAS and Theramex France SAS v Agence nationale deDecision
Recitals 2, 3, 9, 10 and 15 of Directive 2001/83 read as follows: The essential aim of any rules governing the production, distribution and use of medicinal products must be to safeguard public health However, this objective must be …
23 Apr 2026 · 62024CJ0118
Opinion of Advocate General Hogan delivered on 11 September 2019. PTC Therapeutics International Ltd v European Medicines Agency.Decision
Regulation in the area of medicinal products aims at reconciling a variety of goals. The first of these is quite obviously the safeguarding of public health, but it is also vital to create incentives to enable pharmaceutical companies to …
11 Sep 2019 · 62018CC0175